Analysis of the vascular responses in a murine model of polycystic ovary syndrome

Journal of Endocrinology

Volumn 218, Issue 2, 2013, Pages 205-213

  Labruijere, Sieneke ^a   van Houten, E Leonie A F ^a   de Vries, René ^a   Musterd Bagghoe, Usha M ^a   Garrelds, Ingrid M ^a   Kramer, Piet ^a   Danser, A H Jan ^a   Villalón, Carlos M ^b   Visser, Jenny A ^a   MaassenVanDenBrink, Antoinette ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

aorta; dihydrotestosterone; non genomic mechanisms; PCOS; vasorelaxation

Indexed keywords

ACETYLCHOLINE; ANDROGEN RECEPTOR; ANDROSTANOLONE; CALCITONIN GENE RELATED PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; N(G),N(G) DIMETHYLARGININE; NITROPRUSSIDE SODIUM; PLACEBO; REACTIVE OXYGEN METABOLITE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG PELLET; ENDOTHELIAL DYSFUNCTION; FEMALE; FORCE; HYPERANDROGENISM; ISOLATED ARTERY; MOUSE; NONHUMAN; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE RELAXATION; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; POLYCYSTIC OVARY SYNDROME; VASODILATION;

EID: 84880687130     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0094     Document Type: Article

References (47)

1. Apparao KB, Lovely LP, Gui Y, Lininger RA & Lessey BA 2002 Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biology of Reproduction 66 297-304. (doi:10.1095/biolreprod66.2.297)
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S & Escobar-Morreale HF 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 85 2434-2438. (doi:10.1210/jc.85.7.2434)
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 89 2745-2749. (doi:10.1210/jc.2003-032046)
4. Bayrak T, Dursun P, Bayrak A, Gultekin M, Kolusari A, Cakir E, Ozyurt M & Zeyneloglu HB 2012 Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factoracetylhydrolase (PAF-AH) activity in non-obese women with PCOS. Gynecological Endocrinology 28 874-878. (doi:10.3109/09513590.2012.683068)
5. Bennett NC, Gardiner RA, Hooper JD, Johnson DW & Gobe GC 2010 Molecular cell biology of androgen receptor signalling. International Journal of Biochemistry & Cell Biology 42 813-827. (doi:10.1016/j.biocel.2009.11.013)
6. Carmina E, Rosato F, Janni A, Rizzo M & Longo RA 2006 Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 91 2-6. (doi:10.1210/jc.2005-1457)
7. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, KaramanisN, Hatzistilianou M, Katsikis I & Panidis D 2008 The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 196 958-965. (doi:10.1016/j.atherosclerosis.2007.03.002)
8. Chinnathambi V, Balakrishnan M, Ramadoss J, Yallampalli C & Sathishkumar K 2013 Testosterone alters maternal vascular adaptations: role of the endothelial NO system. Hypertension.
9. Davis SR, Knight S, White V, Claridge C, Davis BJ & Bell R 2002 Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecological Endocrinology 16 443-446.
10. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED & Bartzis MI 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 84 4006-4011. (doi:10.1210/jc.84.11.4006)
11. Durik M, Kavousi M, van der Pluijm I, Isaacs A, Cheng C, Verdonk K, Loot AE, Oeseburg H, Bhaggoe UM, Leijten F et al. 2012 Nucleotide excision DNA repair is associated with age-related vascular dysfunction. Circulation 126 468-478. (doi:10.1161/CIRCULATIONAHA.112.104380)
12. Eftekhari S & Edvinsson L 2010 Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Therapeutic Advances in Neurological Disorders 3 369-378. (doi:10.1177/1756285610388343)
13. Fleming I 2010 Molecular mechanisms underlying the activation of eNOS. Pflügers Archiv: European Journal of Physiology 459 793-806. (doi:10.1007/s00424-009-0767-7)
14. Friederich JA & Butterworth JF 1995 Sodium nitroprusside: twenty years and counting. Anesthesia and Analgesia 81 152-162.
15. Furchgott RF & Zawadzki JV 1980 The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 373-376. (doi:10.1038/288373a0)
16. Glueck CJ, Morrison JA, Goldenberg N & Wang P 2009 Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism 58 714-721. (doi:10.1016/j.metabol.2009.02.005)
17. Goodarzi MO, Quinones MJ, Azziz R, Rotter JI, Hsueh WA & Yang H 2005 Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertility and Sterility 84 766-769. (doi:10.1016/j.fertnstert.2005.03.051)
18. Goodarzi MO, Dumesic DA, Chazenbalk G & Azziz R 2011 Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews. Endocrinology 7 219-231. (doi:10.1038/nrendo.2010.217)
19. de Groot PC, Dekkers OM, Romijn JA, Dieben SW & Helmerhorst FM 2011 PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Human Reproduction Update 17 495-500. (doi:10.1093/humupd/dmr001)
20. van Houten EL, Kramer P, McLuskey A, Karels B, Themmen AP & Visser JA 2012 Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 153 2861-2869. (doi:10.1210/en.2011-1754)
21. Hudecova M, Holte J, Olovsson M, Lind L & Poromaa IS 2010 Endothelial function in patients with polycystic ovary syndrome: a long-term follow-up study. Fertility and Sterility 94 2654-2658. (doi:10.1016/j.fertnstert.2010.02.048)
22. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A & Michalis LK 2005 Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 90 5088-5095. (doi:10.1210/jc.2005-0151)
23. Keller J, Mandala M, Casson P & Osol G 2011 Endothelial dysfunction in a rat model of PCOS: evidence of increased vasoconstrictor prostanoid activity. Endocrinology 152 4927-4936. (doi:10.1210/en.2011-1424)
24. Lakhani K, Leonard A, Seifalian AM & Hardiman P 2005 Microvascular dysfunction in women with polycystic ovary syndrome. Human Reproduction 20 3219-3224. (doi:10.1093/humrep/dei199)
25. Lakhani K, Yang W, Dooley A, El-Mahdi E, Sundaresan M, McLellan S, Bruckdorfer R, Leonard A, Seifalian A & Hardiman P 2006 Aortic function is compromised in a rat model of polycystic ovary syndrome. Human Reproduction 21 651-656. (doi:10.1093/humrep/dei399)
26. Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, Lonn M & Stener-Victorin E 2007 A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 148 3781-3791. (doi:10.1210/en.2007-0168)
27. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ & Celermajer DS 1998 Vascular reactivity is impaired in genetic females taking high-dose androgens. Journal of the American College of Cardiology 32 1331-1335. (doi:10.1016/S0735-1097(98)00416-1)
28. Meyer MR, Haas E, Prossnitz ER & Barton M 2009 Non-genomic regulation of vascular cell function and growth by estrogen. Molecular and Cellular Endocrinology 308 9-16. (doi:10.1016/j.mce.2009.03.009)
29. Mulvany MJ & Halpern W 1977 Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circulation Research 41 19-26. (doi:10.1161/01.RES.41.1.19)
30. Rodin DA, Bano G, Bland JM, Taylor K & Nussey SS 1998 Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clinical Endocrinology 49 91-99. (doi:10.1046/j.1365-2265.1998.00492.x)
31. Roe ND & Ren J 2012 Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vascular Pharmacology 57 168-172. (doi:10.1016/j.vph.2012.02.004)
32. Roland AV, Nunemaker CS, Keller SR & Moenter SM 2010 Prenatal androgen exposure programs metabolic dysfunction in female mice. Journal of Endocrinology 207 213-223. (doi:10.1677/JOE-10-0217)
33. Sara L, Nadasy GL, Antal P, Monori-Kiss A, Szekeres M, Masszi G, Monos E & Varbiro S 2012 Pharmacological reactivity of resistance vessels in a rat PCOS model-vascular effects of parallel vitamin D(3) treatment. Gynecological Endocrinology 28 961-964. (doi:10.3109/09513590.2012.683079)
34. Sasaki A, Emi Y, Matsuda M, Sharula, Kamada Y, Chekir C, Hiramatsu Y & Nakatsuka M 2011 Increased arterial stiffness in mildly-hypertensive women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research 37 402-411. (doi:10.1111/j.1447-0756.2010.01375.x)
35. Simonsen U, Christensen FH & Buus NH 2009 The effect of tempol on endothelium-dependent vasodilatation and blood pressure. Pharmacology & Therapeutics 122 109-124. (doi:10.1016/j.pharmthera. 2009.02.002)
36. Soyman Z, Noyan V, Tulmac M, Yucel A, Sagsoz N, Bayrak T, Bayrak A & Cakir E 2011 Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome. Fertility and Sterility 95 1067-1072. (doi:10.1016/j.fertnstert.2010.12.011)
37. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF & Teede HJ 2013 Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction 28 777-784. (doi:10.1093/humrep/des463)
38. Suzuki M, Takamisawa I, Yoshimasa Y & Harano Y 2007 Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Research and Clinical Practice 76 12-17. (doi:10.1016/j.diabres.2006.07.033)
39. Villalon CM & Centurion D 2007 Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn-Schmiedeberg's Archives of Pharmacology 376 45-63. (doi:10.1007/s00210-007-0179-1)
40. Villalon CM & Olesen J 2009 The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacology & Therapeutics 124 309-323. (doi:10.1016/j.pharmthera.2009.09.003)
41. Villavicencio A, Bacallao K, Avellaira C, Gabler F, Fuentes A & Vega M 2006 Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecological Oncology 103 307-314. (doi:10.1016/j.ygyno.2006.03.029)
42. Vitale C, Fini M, Speziale G & Chierchia S 2010 Gender differences in the cardiovascular effects of sex hormones. Fundamental & Clinical Pharmacology 24 675-685. (doi:10.1111/j.1472-8206.2010.00817.x)
43. Wilcox CS 2010 Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacology & Therapeutics 126 119-145. (doi:10.1016/j.pharmthera.2010.01.003)
44. Wild RA 2002 Long-term health consequences of PCOS. Human Reproduction Update 8 231-241. (doi:10.1093/humupd/8.3.231)
45. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA 2010 Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 95 2038-2049. (doi:10.1210/jc.2009-2724)
46. Zafarullah M, Li WQ, Sylvester J & Ahmad M 2003 Molecular mechanisms of N-acetylcysteine actions. Cellular and Molecular Life Sciences 60 6-20. (doi:10.1007/s000180300001)
47. Zurvarra FM, Salvetti NR, Mason JI, Velazquez MM, Alfaro NS & Ortega HH 2009 Disruption in the expression and immunolocalisation of steroid receptors and steroidogenic enzymes in letrozole-induced polycystic ovaries in rat. Reproduction, Fertility, and Development 21 827-839. (doi:10.1071/RD09026)